Aldeyra Therapeutics: ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
The FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises.
Read full article »
President & CEO
Todd C. Brady
Aldeyra Therapeutics develops and commercializes medicines for the treatment of retinal inflammation, lymphoproliferative disease and cancer.
Read more